IMPORTANCE Cannabidiol (CBD) has antipsychotic effects in humans, but how these are mediated in the brain remains unclear.
and modulates the function of neurotransmitters thought to be critically perturbed in psychosis, including dopamine and glutamate. 11 The constituent of cannabis responsible for its short-term psychotomimetic effects [12] [13] [14] and its association with the development and relapse of psychosis is Δ9-tetrahydrocannabinol (THC). [1] [2] [3] [4] 15, 16 In contrast, cannabidiol (CBD), one of the major nonpsychoactive constituents of cannabis, has broadly opposite neural and behavioral effects. [17] [18] [19] [20] [21] [22] [23] In particular, we have shown that CBD has opposing effects to THC on activation in the striatum during verbal memory 17 and salience processing, 18 on amygdala responses during emotional processing, 17 and on the functional connectivity of these regions. 19 Furthermore, pretreatment with CBD blocks the experimental induction of psychotic symptoms by THC, 17, 20 and clinical studies 24, 25 indicate that CBD has antipsychotic and anxiolytic properties in patients with mental disorders. 7, 8 Cannabidiol was noninferior to antipsychotic medication in a 4-week clinical trial in first-episode psychosis 26 and improved psychotic symptoms when used as an adjunct to antipsychotic medication in a 6-week trial in patients with long-term psychosis. 27 Although there is good evidence that CBD can have beneficial effects on psychotic symptoms, how these effects are mediated in the brain remains unclear. The present study sought to address this issue by examining the effects of CBD in individuals at clinical high risk (CHR) of psychosis. Individuals at CHR typically experience clinically significant psychotic symptoms that are qualitatively similar to those seen in patients with frank psychosis 28 and are associated with high levels of distress. 29 Contemporary preclinical models propose that psychosis involves a perturbation of activity in the medial temporal lobe (MTL) that drives subcortical dopamine dysfunction through projections to the striatum and midbrain. 30 Moreover, neuroimaging studies in individuals at CHR indicate that the later onset of psychosis is linked to alterations in parahippocampal structure 31 and function [32] [33] [34] and to elevated striatal and midbrain dopamine activity.
In the present study, on the basis of previous studies, we expected that participants at CHR would display altered responses in the MTL, midbrain, and striatum relative to healthy control participants. Our main hypothesis was that CBD would attenuate functional abnormalities in this triad of regions. While the MTL is critical for new learning, 35 the midbrain [36] [37] [38] [39] and striatum [39] [40] [41] [42] [43] also play a key role in supporting the encoding and updating of contextual information in memory. Therefore, we used the verbal paired associate (VPA) learning task, which engages these processes and brain regions. 13, 14 Furthermore, transient psychotomimetic effects of THC have been associated with its modulation of striatal 13 and midbrain 14 function, and CBD 17 has been shown to oppose these striatal effects of THC during this task.
Methods

Study Design, Participants, and Procedures
The trial protocol can be found in Supplement 1, and detailed methods can be found in the eMethods and eFigure 1 in Supplement 2. Thirty-three antipsychotic medication-naive participants at CHR 28 were recruited from early intervention services in the United Kingdom. Nineteen age-matched (within 3 years) healthy control participants were recruited by local advertisement. Individuals with a history of psychotic or manic episodes, neurological disorders, or a current DSM-IV diagnosis of substance dependence, IQ less than 70, and contraindication to magnetic resonance imaging (MRI) or treatment with CBD were excluded. Psychopathology was measured using Comprehensive Assessment of At-Risk Mental States (positive and negative symptoms) 28 and State-Trait Anxiety Inventory-State Subscale 44 at baseline before drug administration. Two participants at CHR were excluded, 1 from each of the CBD and placebo groups, after failing to correctly perform the imaging task, resulting in 15 participants in the CBD group and 16 in the placebo group. The study protocol was approved by the National Research Ethics Service Committee of London-Camberwell St Giles. All participants provided written informed consent. Using a parallel-group, double-blind, placebo-controlled design, participants at CHR were randomized to either CBD or placebo treatment and received a single oral dose of 600 mg of CBD (THC-Pharm), a dose previously effective in established psychosis, 26 or an identical placebo capsule, respectively. Three hours after taking the CBD or placebo capsule, participants underwent functional MRI (fMRI) while performing a VPA task that we have previously used in conjunction with fMRI and pharmacological challenge, 13, 14 including CBD administration 17 (eMethods and eFigure 2 in Supplement 2).
Control participants were investigated under identical conditions but did not receive any study drug. All participants were asked to have refrained from consuming cannabis for 96 hours, alcohol for a minimum of 24 hours, and nicotine for 6 hours before scanning as well as any other recreational drugs for 2 weeks before the study day. A urine sample prior to scanning was used to screen for use of illicit drugs.
The VPA task (eMethods in Supplement 2) comprised 3 conditions (encoding, recall, and baseline), with stimuli presented visually in blocks and accuracy of responses recorded online. During encoding, participants were shown word pairs and asked to say yes or no aloud after each pair to indicate whether they went well together. The same word pairs were presented in the encoding condition 4 times so that the associations could be learned over repeated blocks. During recall, 1 of the words from previously presented pairs was shown, and participants were asked to say the word that it had previously been associated with. Participants said "pass" if they could not recall the missing word. During baseline, participants viewed a pair of blank blue rectangles of identical dimensions as in the encoding/recall condition. For each participant, the blood oxygen level-dependent (BOLD) hemodynamic response of the brain during each encoding and recall block, measured using a Signa HDx 3.0-T MRI scanner (General Electric; gradient echo sequence axially; 39 × 3-mm slices; 3.3-mm slice gap; 30-millisecond echo time; compressed acquisition with a 2-second repetition time and 3-second silence), was contrasted with the response during the baseline condition.
Analysis
Functional MRI data were analyzed with XBAM software, version 4.1, using a nonparametric approach to minimize assumptions (https://www.kcl.ac.uk/ioppn/depts/neuroimaging /research/imaginganalysis/Software/XBAM.aspx). 45, 46 Images were corrected for motion 47 and spatially smoothed, and the experimental design was convolved with 2 γ-variate functions to model the BOLD response. Using the constrained BOLD effects model, a best fit between the weighted sum of these convolutions and the change over time at each voxel was computed. 48 Following least-squares fitting of this model to the time series at each voxel, a sum of squares (SSQ) ratio statistic (ratio of the model component to the residual sum of squares) was estimated for the encoding and recall conditions relative to baseline. Significance of the estimated SSQ values at each voxel was determined by permutation tesing. 49 ,50 Sum of squares ratio maps for each individual were transformed into standard stereotactic space, 45, 51 and group activation maps were computed for each group in each drug condition by determining the median SSQ ratio at each voxel (over all individuals) in the observed and permuted data maps. Group activation maps for each condition were compared against each other (placebo vs control and CBD vs placebo) using nonparametric repeatedmeasure analysis of variance. 45 The voxelwise statistical threshold was set at P = .05, and the clusterwise thresholds were adjusted to ensure that the number of false-positive clusters per brain would be less than 1; regions that survived this critical statistical threshold and the corresponding P values are reported. The BOLD response in each participant was modeled using only trials associated with correct responses in the recall condition. To test the hypothesis that activation in the CBD group would be intermediate between that of the control and placebo groups, we examined whether a linear relationship in brain activation (placebo group activation > CBD group activation > control group activation or placebo group activation < CBD group activation < control group activation) existed within the whole brain.
Recall performance was analyzed using repeatedmeasures analysis of variance. Correlational analysis between recall score and brain activation was conducted using 2-tailed Pearson test. Significance was set at a P value less than .05.
Results
There were no significant group differences between the placebo and control groups or the placebo and CBD groups in most demographic and clinical variables. However, the placebo group had fewer years of education than the control group ( Table 1) .
fMRI Results
In control participants, relative to the baseline condition, the encoding condition was associated with activation in the left anterior cingulate cortex, the right caudate, the left precentral gyrus, and the cuneus (eTable 1 in Supplement 2). The recall condition relative to the baseline condition was associated with activation in the left parahippocampal and the left transverse temporal gyri and with decreased activation in the left middle occipital, the right lingual, and the inferior frontal gyri (eTable 2 in Supplement 2).
Differences in Activation Associated With the CHR State (Placebo vs Control)
Encoding During the encoding condition, participants receiving placebo showed greater activation than control participants in the right middle frontal gyrus and adjacent parts of the inferior frontal gyrus and insula; the left insula/claustrum and the adjacent inferior frontal gyrus and putamen; the right precentral gyrus and the adjacent postcentral gyrus and inferior parietal lobule; and the left cerebellum and the adjacent lingual gyrus (Table 1 ; Figure 1A ). Relative to participants in the placebo group, controls showed greater activation in the right subcallosal gyrus/caudate head; the left anterior cingulate; the right caudate tail extending to the posterior cingulate cortex; and in the right precuneus and cuneus (Table 2; Figure 1A ).
Recall
During the recall condition, participants receiving placebo showed greater activation than controls in clusters encompassing the right inferior frontal, middle frontal, and precentral gyri and the insula; the right cuneus, fusiform, and lingual gyri and the posterior cingulate gyri; and the left cerebellum and middle occipital and fusiform gyri (Table 2; Figure 1B ). Controls showed greater activation in 4 clusters in the left hemisphere. These involved the parahippocampal gyrus, the midbrain, the cerebellum, and the thalamus; the superior temporal and middle temporal gyri; the superior and transverse temporal gyri; and the middle frontal gyrus (Table 2; Figure 1B ).
Effect of CBD on Activation in Participants at CHR (CBD vs Placebo)
Encoding During the encoding condition, participants at CHR in the placebo group showed greater activation than those in the CBD group in a cluster in the left parahippocampal gyrus that extended into the superior temporal gyrus and the cerebellum. However, participants in the placebo group showed less activation than those in the CBD group in the precentral gyri (Table 2; Figure 1C ).
Recall
During the recall condition, participants in the placebo group showed less activation than those in the CBD group in 3 clusters, with foci in the left cingulate gyrus and the adjacent body of caudate; the right precentral gyrus extending to the cingulate gyrus; and in the medial frontal gyrus (Table 2; Figure 1D ). There were no clusters of greater activation in the placebo group compared with the CBD group.
Between-Group Linear Analysis
This analysis identified clusters where there was a linear pattern of activation across the 3 groups of participants. In these clusters, activation in the CBD group was intermediate to that in the placebo and control groups.
Encoding
There were 7 clusters where encoding-related engagement was greatest in the placebo group, lowest in the control group, and at an intermediate level in the CBD group. These involved the right inferior frontal and middle frontal gyri and the insula; the left insula and putamen; 3 clusters in the precentral gyri; the right fusiform gyrus and adjacent cerebellum; and the left cerebellum and fusiform gyrus ( Table 3 ; Figure 2A and B) (eFigure3inSupplement 2). The right inferior frontal gyrus, left insula, and precentral clusters overlapped with the regions where participants receiving placebo showed increased activation during encoding relative to the control group in the earlier paired comparison. There were 4 clusters where there was a linear betweengroup relationship in the opposite direction (ie, lowest in the placebo group, highest in the control group, and at an intermediate level in the CBD group). These involved the left Figure 2A and B) (eFigure 3 in Supplement 2). All 4 clusters overlapped with clusters where controls had shown greater activation than the placebo group during encoding in the previous paired comparison.
Recall
In 3 clusters, recall-related engagement was greatest in participants receiving placebo, lowest in controls, and at an intermediate level in participants receiving CBD. These clusters comprised the right inferior frontal gyrus extending to the ipsilateral middle frontal gyrus and insula; the precuneus extending to the cuneus, lingual, middle occipital, and fusiform gyri and the cerebellum on the right side; and the cerebellum extending to the fusiform, lingual, and inferior occipital gyri on the left side (Table 3 ; Figure 2C and D) (eFigure 3 in Supplement 2). All 3 clusters overlapped with clusters where the placebo group had shown greater activation than controls during recall in the paired comparison. Conversely, there were 4 clusters where activation was lowest in the placebo group, greatest in the control group, and at an intermediate level in the CBD group. These included the left parahippocampal gyrus, the midbrain, and the cerebellum; the left thalamus; the left transverse temporal gyrus extending to the superior temporal gyrus; and the left precentral and cingulate gyri and caudate body (Table 3 ; Figure 2C and D) (eFigure 3 in Supplement 2). The left parahippocampal gyrus and transverse temporal gyrus clusters overlapped with clusters where controls had shown greater activation than participants receiving placebo during recall in the paired group comparison.
Relationship Between Recall Performance and Brain Activation
Across all participants, the total recall score was directly correlated with the level of left parahippocampal activation during recall (r = 0.28; P = .046) (eResults in Supplement 2).
Discussion
As expected and in line with data from previous neuroimaging comparisons of participants at CHR of psychosis with controls, 52-54 we found that under placebo conditions, participants at CHR showed differential activation relative to controls in several regions. These regions of differential response included the 3 areas thought to be critical to the pathophysiology of the CHR state: the striatum (during verbal encoding) and the MTL and midbrain (during verbal recall). To test our main hypothesis, we identified regions where there was a linear pattern of activation across the 3 groups such that the level of activation in participants at CHR receiving CBD was intermediate to that of participants at CHR receiving placebo and control participants. We found that this pattern of differential activation was evident in the striatum during encoding and in the parahippocampal cortex and midbrain during recall. Moreover, these regions of differential activation overlapped with the areas where participants at CHR receiving placebo had shown altered activation in the paired comparison with controls. These findings suggest that during verbal encoding, the administration of a single dose of CBD attenuated the reduction in the striatal response evident in participants at CHR receiving placebo relative to controls. Similarly, administration of CBD appeared to attenuate the reduction in the parahippocampal and midbrain responses during verbal recall that was seen in participants receiving placebo relative to controls. Although this interpretation is cautious because the findings are based on cross-sectional as opposed to within-participant comparisons, these data suggest that in these regions, CBD may partially normalize responses to verbal encoding and recall in individuals at CHR. As there were no significant differences in memory performance, this differential activation was not attributable to differential task performance. Short-term effects of CBD on responses in these areas in participants at CHR are consistent with previous data from 2 studies that used a single dose of CBD in healthy volunteers. 17, 18 These studies indicated that in controls, CBD augmented parahippocampal and striatal activation during the same learning task 17 as used in the present study and had a similar effect on parahippocampal and striatal responses during an attentional salience task. 18 In both of these studies, the administration of a single dose of THC induced transient psychotic symptoms, and the effect of THC on parahippocampal and striatal activation was the opposite to that of CBD. Preclinical models suggest that overactivity in the MTL region drives subcortical dopamine dysfunction through projections to the striatum and midbrain.
55,56 Moreover, neuroimaging studies in individuals at CHR indicate that the subsequent onset of psychosis is linked to alterations in MTL structure 31 and function 32, 34 and to elevated striatal and midbrain dopamine function. 57-59 Effects of CBD on parahippocampal, striatal, and midbrain function in participants at CHR are thus of particular interest, as these areas may play a critical role in the pathophysiology of psychosis. 30 A partial normalization of dysfunction in these regions could contribute to the therapeutic effects of CBD that have been reported in patients with psychosis 26, 27 and anxiety disorders. 25 The molecular mechanism of action that may underlie the effects of CBD in individuals at CHR is unclear. Cannabidiol has effects on a number of signaling pathways, 11, 60, 61 including on the CB1 receptors, 62,63 and may modulate glutamatergic neurotransmission, particularly in the hippocampus, through multiple pathways 64-66 and striatal glutamatergic and CB1 receptor expression. 67 In patients with psychosis, the effects of CBD on psychotic symptoms have been associated with its influence on levels of the endogenous cannabinoid anandamide. 26 Therefore, future studies need to investigate the neurochemical and receptor-level mechanisms that may underlie the antipsychotic effects of CBD. Across all participants, the level of activation in the left parahippocampal cortex during verbal recall was directly correlated with total recall score during the task, consistent with the key role of this region in relational memory binding and retrieval 68, 69 and in supporting association-based recall.
70
Attenuated parahippocampal engagement in participants receiving placebo is consistent with meta-analytic and independent evidence from studies in patients with established psy- chotic disorders, such as schizophrenia, [71] [72] [73] and in studies in those at clinical 34, 74 and familial/genetic 73,75 risk of psychosis (eDiscussion in Supplement 2).
Limitations
Our study had limitations. The most elegant way to investigate the short-term effects of CBD on psychotic symptoms would have been to use a within-participant, repeatedmeasures design as it would have allowed us to properly test whether a single dose of CBD normalizes the dysfunction in brain regions linked to psychosis. However, while such a design would have been ideal as opposed to a cross-sectional design, as in our previous studies using CBD in healthy volunteers, [17] [18] [19] it would have been difficult to scan participants at CHR twice under 2 different drug conditions. The participants at CHR who were investigated in the CBD arm in the present study were not compared with the same participants while they were receiving placebo treatment but were instead compared with a separate group of participants at CHR receiving placebo. As a result, we cannot be certain that CBD effects in the striatum, parahippocampal cortex, and midbrain in participants receiving CBD (that we have shown as being intermediate compared with the placebo and control groups) reflected a partial normalization of dysfunction in these regions that predated CBD treatment. Therefore, this needs confirmation in future studies using a withinsubject, repeated-measures design and with the same individuals at CHR tested with both placebo and CBD treatment. Nevertheless, it is worth noting that the 2 CHR groups were comparable on various demographic and clinical measures at baseline, and we were able to define regions where participants at CHR showed altered activation while receiving placebo relative to controls and then showed that administration of CBD modulated activation in a subset of these regions. We were also unable to examine whether the effects of CBD differed between participants at CHR who later transitioned to psychosis compared with those who did not because only 1 patient transitioned per treatment arm. Future studies may investigate this in independent, larger cohorts or if more patients transition to psychosis from the present sample.
Another important caveat worth considering relates to the rapid changes in cerebral perfusion that are known to occur with a single dose of psychoactive drugs, such as antipsychotic medications.
76,77 Therefore, one cannot be certain whether the short-term effects of CBD observed here are consequences of its effects on local neuronal activity during the fMRI task as opposed to more general effects on cerebral blood flow. The fMRI acquisition and data analysis steps were designed to control for any nonspecific/generalized effects of CBD on regional perfusion, as we compared the effects of CBD during an active task condition (eg, encoding or recall) with its effects during a control (baseline) condition. While there is no reason to think that the short-term effects of CBD on regional perfusion would differ systematically between different task conditions, we cannot completely rule out this possibility. It is also unclear whether the effects of CBD will persist after longer-term dosing. Therefore, future studies investigating the effects of sustained dosing with CBD are warranted. Finally, although we did not find an effect of CBD on memory task performance, we used a relatively easy verbal learning task, and the study was not powered to demonstrate differences at a behavioral level. A 2018 study 27 in patients with schizophrenia found a trend for improved cognitive performance after 6 weeks of treatment with CBD, but the present study involved a single dose of CBD, and cognitive deficits in individuals at CHR are less severe than in patients with psychosis.
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Conclusions
This study suggests that a single dose of CBD in an experimental setting may partially normalize dysfunction in the MTL, striatum, and midbrain in individuals at CHR of psychosis. It would be useful to now investigate whether similar modulatory effects are evident in patients who have received a course of treatment with CBD in a clinical setting. 
Schoeler T, Monk
PROTOCOL I. BACKGROUND:
While dopaminergic(1-4) and glutamatergic(1-10) neurotransmitter systems and their receptors have traditionally been investigated in the context of their role in psychosis, another receptor system that has not attracted as much attention from researchers until recently has been the endocannbinoid system. CB1 receptor, the main central cannabinoid receptor (11) is ubiquitous in distribution and plays a role in modulating the function of several neurotransmitters including dopamine and glutamate (12) . A growing body of epidemiological studies have also linked regular frequent use of cannabis, as a risk factor for the development of schizophrenia (13) . The main central molecular target for delta-9-THC, the major psychoactive ingredient in cannabis, responsible for its psychotogenic effects is the CB1 receptor, where it has a partial agonist effect (12) . Evidence has also emerged of alterations in the endocannabinoid system in those with psychosis (14-17). However, the precise role of alterations of the endocannabinoid system in psychosis is unclear. One way to investigate the relationship between dynamic alterations of the endocannabinoid system and psychosis is to examine this under experimental conditions in individuals who are at ultra-high risk for psychosis following challenge with cannabinoids. Individuals at ultra high-risk of psychosis (UHR) experience brief or subclinical psychotic experiences that have been shown to predict the onset of schizophrenia and related psychotic disorders (18) (19) (20) , with the largest naturalistic follow-up studies indicating that around 35% of subjects will develop a frank psychotic disorder, majority of them developing this within 2 years (21, 22) . This population is an ideal group to investigate the neurobiological basis of psychosis and its relationship to endocanabinoid alterations. Although they are experiencing acute psychotic symptoms, they are usually na•ve to antipsychotic medication, and are functionally intact and able to tolerate and cooperate with complex neuroimaging and other experimental investigations. In contrast, it is difficult to recruit patients with schizophrenia who have not already been exposed to antipsychotic medication, which would confound interpretation of data from studies involving administration of cannabinoids. However, because of the evidence linking cannabis use and delta-9-THC with increased risk for psychosis and psychotic symptoms respectively, it would be unethical to employ either cannabis or delta-9-THC as the challenge drug to perturb the endocannabinoid system. On the other hand, Cannabidiol, another cannabinoid that has attracted attention in recent years and is a non-psychoactive compound, may be an useful tool to safely modulate the endocannabinoid system in man. While delta-9-THC is a partial agonist at cannabinoid (CB1) receptors, recent data suggests that Cannabidiol may have an inverse agonist/antagonist effect at the same receptors, in addition to its various other possible mechanisms of action (12) . Consistent with this, cannabidiol also has opposite symptomatic and neural effects to that of delta-9-THC. For example, using a repeated measure, within-subject, placebo-controlled design and combining fMRI and pharmacological challenge with the two main components of cannabis, delta-9-THC and Cannabidiol, we have found that delta-9-THC induced psychotic and anxiety symptoms in healthy individuals and that these effects were directly related to its effects on activation in the striatum during verbal learning (23) and attentional salience processing (24) and the amygdala during emotional (fear) processing (24, 25) tasks respectively. Cannabidiol had opposite effects to delta-9-THC on striatal and amygdala activation during the same cognitive tasks (24, 25) (Figure 1 ) in the same individuals, was well-tolerated, did not induce psychotic or anxiety symptoms and did not cause intoxication. Furthermore, in a separate pilot sample, employing a placebo-controlled design, we have shown that cannabidiol can block the induction of psychotic symptoms by delta-9-THC in healthy individuals (25) . This is also consistent with independent evidence that Cannabidiol can block the symptomatic effects (26, 27) and neurocognitive impairments (28) (29) (30) caused by delta-9-THC (26). Consistent with human data, animal studies have also demonstrated that Cannabidiol may promote hippocampal neurogenesis (31) and rescue memory function both following acute and chronic administration (32) in animal models of cognitive impairment as well as have anti-aversive effects in animal models of anxiety (33) . Also, a wealth of evidence exists regarding the safety of cannabidiol following acute and longer-term dosing in man (34) . Thus cannabidiol is a safe, well-tolerated cannabinoid that may allow investigation of the effects of acute as well as short-term modulation of the endocannabinoid system on the neural substrates for psychosis to understand the precise role of alterations in this system in schizophrenia.
In this study, we propose to examine the effects of acute as well as short-term modulation of the endocannabinoid system in the UHR subjects by employing an experimental design that combines pharmacological challenge with functional neuroimaging using a parallel-group, double-blind, randomized, placebo-control design.
Figure 1:
Opposite effects of delta-9-THC and CBD relative to placebo on prefrontal, left caudate and hippocampal activation (BOLD response) during visual oddball salience processing. The left side of the brain is shown on the left side of the images.
II. OBJECTIVES:
The principal objective of this exploratory study is to investigate the precise relationship between dynamic alterations of the endocannabinoid system by administering CBD, an inverse agonist/ antagonist cannabinoid, and the functioning of the neural substrates for learning, salience and emotional processing that may underlie the psychotic and anxiety symptoms experienced by the UHR population. Furthermore, we propose to examine whether treatment with CBD is associated with an effect on plasma endocannabinoid [Anandamide, 2-Arachidonoylglycerol (2-AG), Palmitoylethanolamine (PEA), Oleoyl-ethanolamine (OEA)] levels over the same time period.
III. METHODOLOGY:
We propose to employ complementary strategies to address the objectives of the study by examining the effects of CBD on different parameters of interest acutely and following steady-state dosing: 1) neurocognitive and neurochemical mechanisms for the symptomatic effects employing functional MRI and proton magnetic resonance spectroscopy ( 1 H-MRS) 2) effect on psychotic and anxiety symptoms following symptom-induction strategies, and 3) effect on endocannabinoid signaling by measuring plasma endocannbinoid levels.
Specifically, we propose to examine whether acute administration of CBD can modulate the neurocognitive and neurochemical substrates underlying psychotic and anxiety symptoms by examining the acute effect of CBD on neural activation during learning, salience and emotional (fear) processing tasks in UHR individuals with an at-risk mental state (ARMS) for psychosis. Furthermore, we propose to examine whether these acute effects persist or change in the shortterm, after continued administration of CBD for 3 weeks, by examining the change in psychotic and anxiety symptom ratings and plasma endocannabinoid levels relative to baseline in the two treatment groups as well the effect on their neurocognitive and neurochemical substrates. Effects observed under steady-state conditions following 3 weeks treatment with CBD will confirm that the acute effects of CBD relative to placebo noticed on day 1 of the study are not non-specific effects unrelated to the perturbation of the endcannabinoid system. Although the present study employs a double-blind, placebo-controlled, randomized design similar to a clinical trial, unlike in a clinical trial, the objective of the present study is to test both the acute effects as well as the non-acute effects of short-term modulation of the cannabinoid system using a pharmacological challenge strategy. Hence, we have decided to obtain the measurements at 2 different time-points: one for measuring the acute effects and another for non-acute short-term effects. Another rationale behind this approach is that this is a proof-of-concept, pilot study. Hence, the objective is to optimize the acquisition of usable and meaningful data and mitigate the potential risks related to attrition of study participants in a complex study of this nature. Ideally, for the purposes of this experimental approach where one is looking for a better understanding of the biology of the disease (especially putative causal role of the endocannabinoid system in psychosis) as well as signals that may inform Ôgo/ no-goÕ decisions regarding future studies, one would like to employ a design whereby it is possible to measure the effects of steady-state levels of the active compound on symptoms as well as the neural mechanisms underlying those symptoms at the earliest measurable time-point. At the same time, one would like to obtain evidence of effects over a period that resonates with clinical reality, given the chronicity of the condition. While data obtained at day 21 is likely to be particularly informative in terms of understanding the disease biology, we are also mindful that because of the design of the study (i.e., assessments over a 3-week period) and nature of illness in the participant population, drop-outs are likely to occur over the course of this study. Inclusion of outcome measures at 2 time-points would ensure that we would still have adequate and meaningful data consistent with the proof-of-concept nature of the study, even if there were significant numbers of drop-outs. While the day 1 measures would allow an early glimpse at the biology and help mitigate the risk of attrition, the day 21 measures would help separate any positive signals from noise.
Hypotheses: We will test the following hypotheses in humans: 1) Relative to the placebo condition, administration of CBD will acutely modulate medial temporal, striatal, midbrain, cingulate and prefrontal activation measured using fMRI (BOLD response) during learning, salience and emotional (fear) processing tasks in UHR individuals. 2) Relative to the placebo condition, administration of CBD will acutely modulate hippocampal glutamate levels (measured using 1 H-MRS) in UHR individuals. 3) Relative to the placebo treatment group, CBD treatment group will demonstrate a change in the medial temporal, striatal, midbrain, cingulate and prefrontal activation during learning, salience and emotional (fear) processing following 3 weeks of treatment in the UHR subjects. 4) Relative to the placebo treatment group, CBD treatment group will demonstrate a change in the hippocampal glutamate levels (indexed using 1 H-MRS) following 3 weeks of treatment in the UHR subjects. 5) Relative to the placebo treatment group, CBD treatment group will demonstrate a change in the severity of baseline UHR symptoms and endocannabinoid levels following 3 weeks of treatment and post-induction psychotic and anxiety symptoms following 1 and 3 weeks of treatment in the UHR subjects.
Subjects:
Inclusion criteriai) Forty right-handed UHR individuals (35) between 18-35 years satisfying CAARMS criteria (36) will be recruited locally from OASIS (www.oasislondon.com), a large clinical service for this group. ii) Most UHR subjects presenting to OASIS are medication-na•ve, and only those who are na•ve to antipsychotic medication will be included. Use of cannabis and other illicit substances will be assessed using a structured clinical interview(37). Exclusion criteria-Include i) history of previous psychotic disorder or manic episode, ii) a current DSM IV diagnosis of substance dependence (except cannabis dependence), iii) neurological disorders (eg., epilepsy) or severe intercurrent illness that may put the person at risk, iv) IQ of less than 70, v) female subject who is unwilling to use two forms of contraception (one of which must be a barrier contraception), pregnant, lactating or planning pregnancy during the course of the study and 3 months from the date of the last dose and a male subject whose partner is of child-bearing potential and unwilling to use a barrier method of contraception along with their partner. Identification of participants-All patients under care of the early intervention services (OASIS team) who have expressed interest to their care-coordinator in taking part in the study and have agreed to be contacted will be contacted telephonically by study staff. If they express interest in taking part following brief telephonic explanation of the study, arrangement will be made for faceto-face meeting for detailed explanation of the study and for the purposes of giving study information sheet for the purposes of consenting. They would be further contacted after 1-2 days (at least 24 hours later) to arrange for a visit in case they were still interested. Written informed consent will be obtained on the day of the first study visit.
Design: Employing a parallel-group, double-blind design, subjects will be randomly allocated to one of two groups: 1) Cannabinoid challenge group and 2) placebo group. They will receive either 600 mg of CBD, a dose that has been employed with minimal side-effects such as mild drowsiness in healthy individuals (25) or placebo, administered once a day orally in identical capsules for 3 weeks. They will take part in experimental sessions under identical conditions on the first day as well as the last day (day 21) of the study, 2 hours after administration of the first dose of the drug. Outcome measures will be recorded and venous blood samples to monitor CBD levels will be obtained at various time-points (detailed below) on day 1 and day 21 (end of study) as well as on day 8 and day 15 of the study. Regular telephone contacts will be maintained over the first week of the study to ensure continued compliance and monitor side-effects.
Procedure and Measurements:
Measures: Psychopathological ratings: Comprehensive assessment of at-risk mental states (CAARMS) (35, 36) , State-trait Anxiety Inventory (STAI) (38) ; Ratings of Functional status: Global assessment of functioning(39); Compliance: pill count; Tolerability: Assessed by self-report of side-effects and the UKU side-effect rating scale(40); Safety bloods: Haematology (Full blood count and Haemoglobin) and Biochemistry (Urea & Electrolytes, liver function test, thyroid function test, lipid profile); Vital signs: Heart rate and Blood pressure; Physical examination. MRI scanning: fMRI data will be acquired using the 3T scanner at the Centre for Neuroimaging sciences at the Institute of Psychiatry, KCL, while participants perform a cognitive activation tasks (details below) inside the scanner.
Procedure on day 1 (online session): A urine drug screen for amphetamines, benzodiazepines, cocaine, opiates and THC will be performed on the day of the experimental session and the results recorded. Subjects will also be advised to refrain from using alcohol for 24 hours or nicotine for 6 hours on the day of scanning. Safety blood samples for (routine biochemistry and haematology) will be obtained and physical examination and vital signs recorded on all participants on day 1 before entering the study. Baseline measures will be obtained and then psychopathological measures will be recorded at baseline before drug administration and 120 min, and 300 minutes after the administration of the drug using standard rating scales. CAARMS will be recorded only at baseline. Venous blood samples will be taken just before drug administration, and at 120 min (before entering the MRI scanner), and 300 minutes (after coming out of the MRI scanner) after drug administration to monitor CBD and plasma endocannbinoid levels on both the days. Blood pressure and heart rate will be measured at the same time points. Subjects will enter the MRI scanner at 180 min after administration of the drug, and will be scanned over a 90-minute period to obtain functional MRI and 1 H MRS and arterial spin labelling (ASL) data. Previous work indicates that plasma levels of CBD remain stable over this period following oral administration. Procedure on day 8: Compliance and Tolerability measures will be recorded on day 8 of the study. Venous blood samples to monitor CBD levels will be obtained and vitals signs monitored on these occasions. Safety bloods will be obtained on day 8 and psychopathological ratings will be obtained on day 15 of the study. Participants will also take part in symptom induction experiments. Procedure on day 15: Compliance and Tolerability measures will be recorded. Venous blood samples to monitor CBD levels will be obtained and vital signs monitored on these occasions.. Procedure on day 21 (online and offline session): A urine drug screen for amphetamines, benzodiazepines, cocaine, opiates and THC will be performed on the day of the experimental session and recorded. Subjects will also be advised to refrain from using alcohol for 24 hours or nicotine for 6 hours on the day of scanning. Safety blood samples for (routine biochemistry and haematology) will be obtained and physical examination and vital signs recorded on all participants. Psychopathological measures will be recorded at baseline before drug administration and 120 min, and 300 minutes after the administration of the drug using standard rating scales. CAARMS will be recorded only at baseline. Venous blood samples will be taken just before drug administration, and at 120 min (before entering the MRI scanner) and 300 minutes (after coming out of the MRI scanner) after drug administration to monitor CBD and plasma endocannbinoid levels on both the days. Blood pressure and heart rate will be measured at the same time points. Subjects will enter the MRI scanner at 180 min after administration of the drug, and will be scanned over a 90-minute period to obtain functional MRI and 1 H MRS and ASL data. Previous work indicates that plasma levels of CBD remain stable over this period following oral administration. Participants will take part in offline symptom-induction experiments after completion of MRI scanning.
End of study measures:
In addition to psychopathological ratings and blood samples for CBD levels, that will be obtained on day 21 as described earlier, additional measures will be obtained for function, compliance and tolerability (as detailed earlier). A physical examination will be conducted at the end of the study.
Cognitive Tasks to be performed during scanning
All of these paradigms are well-established and have been used extensively in previous fMRI studies with CBD (23-25). 1. VERBAL PAIRED ASSOCIATES TASK (VERBAL MEMORY)(23) -In an Encoding condition, subjects will be shown word pairs and asked to say (ÔyesÕ or ÔnoÕ) if the words Ôgo togetherÕ. In a subsequent Retrieval condition they are shown one from each pair and asked to say the word that it was previously paired with. Stimuli are presented every 5 s in alternating blocks of 8 pairs and verbal responses will be recorded on-line. (41) -the subject is presented with ÔcueÕ images followed by a white rectangle. They have to press a button as quickly as possible when they see the rectangle. The participants initially start with a fixed quantity of virtual ÔwinningsÕ in pounds sterling, which they can then win or lose depending on response time. Each trial lasts 6 seconds including ÔfeedbackÕ for 1.65 seconds stating how much they have won or lost. There are 2x10 minute sessions consisting of 72 trials, and the subject is paid the cumulative winnings in cash at the end of the day (but not charged for losses). 3. EMOTIONAL (FEAR) PROCESSING TASK(25)-Subjects will be presented with a series of 10 different facial identities, each expressing either a 50% (mildly fearful) or 100% (prototypically fearful) intensity of fear, or a neutral expression. They will be asked to indicate the gender of each face by pressing one of two buttons. Thirty different facial stimuli will be presented twice each for 2 seconds with the order of facial identities and expression type pseudo-randomized such that the same identity or facial expression type will not be presented successively.
ÔMONETARY INCENTIVE DELAYÕ (MID) task
Offline symptom-induction experiments
a) ANXIETY SYMPTOM: Trier Social Stress Test (TSST) (42) . The subject is given 10 minutes to prepare a 5 minute speech and to perform an arithmetic task for a job interview and told to imagine that the interview is for their dream job. They are informed that 2 professional interviewers will be observing for Ôsigns of extroversionÕ while recording their verbal and non-verbal performance on camera for later analysis. After 5 minutes they are asked to perform an arithmetic task during the interview. The interview itself lasts 10 minutes, and the whole process takes 20 minutes in total. The experience is designed to stimulate anxiety, and no information regarding ÔextroversionÕ or arithmetic performance is recorded (the camera is fake). During consenting, the subject is informed that the interview is artificial and solely for research, they are de-briefed following the second interview and again reminded that the entire experience is false and purely for symptom induction. Visual-analogue mood scales (for anxiety) and the self-statement-scale-during-publicspeaking (SSDPS) and state-social-paranoia-scale (SSPS) will be administered over the course of the task and venous blood samples for cortisol analysis will be taken. This task has been shown to result in transient increase in cortisol and in the severity of anxiety symptoms and to be senstitive to the effects of CBD(43).
b) PSYCHOTIC SYMPTOM (PARANOIA) (44, 45) : In this task, participants are asked to wear a Virtual Reality (VR)-headset which simulates a 4-minute journey on the Underground subway. Ambient sounds, conversations, gazes, movements and interactions are simulated. The setting/interactions are deemed 'neutral' by controls, thus any paranoid thinking or suspiciousness is unfounded. The VR experience has been employed in UHR population at our centre and has been popular with participants (46) . In earlier experiments, over 60% of PsP participants [n=63] reported transient paranoid and referential thinking in this setting and provide notably high scores on the state-social-paranoia-scale (SSPS) which we will administer before and after the task and venous blood samples for cortisol analysis will be taken. In these previous experiments, increase in the paranoid and referential thinking within the VR set-up did not persist beyond the experimental session and none of the participants required rescue medications or supportive psychological treatment as a result. Image Acquisition: Echo-planar images depicted blood oxygen level-dependent (BOLD) contrast will be acquired on a General Electric (Milwaukee, USA) 3T HDx MR system at the Institute of Psychiatry, London. During the verbal paired associates task, acquisition will be compressed to allow the processing of auditory/ verbal stimuli in silence.
STATISTICAL ANALYSIS: Study endpoints:
Primary outcome-There are two sets of primary outcomes for this study, measured at day 1 and at day 21, in order to account for the specific design. Day 1-i) fMRI BOLD signal in the hippocampus, striatum and amygdala measured during the memory, MID and emotional (fear) processing tasks on day 1. Day 21- ii) Change in fMRI BOLD signal in the hippocampus, striatum and amygdala measured during the memory, MID and emotional (fear) processing tasks on day 21 relative to that obtained on day 1. Secondary outcomeDay 8-i) Severity of psychotic (measured using SSPS scale) and anxiety (measured using STAI) symptoms following symptom induction strategies on day 8 of the study. Day 21- ii) Change in plasma endocannabinoid (Anandamide, 2-AG, OEA, PEA) levels measured following administration (and before getting inside the scanner) of the last dose of the drug on day 21 relative to that obtained immediately before drug administration on day 1 of the study. iii) Severity of psychotic (measured using CAARMS total score) and anxiety (measured using STAI) symptoms measured following administration of the last dose of the drug (before getting inside the scanner) relative to that obtained immediately before administration of the first dose of the drug on day 1. iv) Change in severity of psychotic (measured using SSPS) and anxiety (measured using STAI) symptoms following symptom induction strategies measured on day 21 relative to that measured on day 1 of the study.
Analysis of behavioural and physiological data: Repeated measures ANOVA (SPSS version 16) will be used to analyse performance during the cognitive paradigms, psychopathological and side-effect ratings and plasma endocannabinoid levels with drug manipulation (placebo / CBD) and time as the factors. Image analysis: Images will be processed then analysed employing non-parametric approach (XBAM version 4; www.brainmap.co.uk). Prof Michael Brammer, one of the developers of the XBAM image analysis package and a collaborator will advise on the statistical aspects of the study. For each paradigm, we will examine the main effect of task and the task x drug interactions. Power Calculation: As this is a proof-of-concept, pilot study, no formal sample size calculation has been performed. The objective of the specific funding stream from the MRC (UK) that has funded this project (Experimental Medicine call for Mental health) is to look for early signals that can then help in making decisions regarding funding further definitive studies. Hence, although we have included a section for power calculation in the protocol, this is based only on neuroimaging (fMRI) evidence in healthy volunteers, as similar data does not exist in this patient population. Based on our previous study in healthy volunteers using a repeated-measures, within-subject design, a sample size of n=15 would be required to detect differences between the placebo and CBD condition on neural activation with an alpha (α) of 0.05 at 90% power and an SD of 0.04 and anticipated minimal difference in means as 0.036 (25) . Thus, a sample of n=40 as proposed in the present study is likely to be sufficient to obtain early evidence of effect of CBD on neural activation measures.
IV. MILESTONES:
We plan to recruit 2-3 subjects a month into the study and estimate completion of recruitment within 1.5 years. Data analysis and drafting of report will be complete over the last 6 months.
V. ETHICS, GOVERNANCE & DATA PROTECTION: Safety and Ethical issues:
Only subjects who have previously used cannabis and who have not experienced any adverse effects will be asked to participate. Pharmacological grade CBD will be administered to study participants. In our previous work, 600 mg of oral CBD was found to be safe in healthy individuals and in collaborative work, 5 mg of IV Cannabidiol blocked the symptomatic effects of THC without having any adverse effects itself (25) . Published human studies have administered CBD for varying durations including over 3 weeks (the duration proposed for the present study) in doses ranging from 150-1500 mg/day in studies (26, 34, 47) involving healthy volunteers and those with psychiatric and neurological conditions without any adverse effects. At the end of testing, we will ensure that subjects are entirely well, instruct them not to drive or operate machinery for 12 hours and they will be transported home by taxi. Although in previous experiments, increase in psychotic symptoms (such as paranoid and referential thinking) within the VR set-up did not persist beyond the experimental session and none of the participants required rescue medications or supportive psychological treatment as a result, a trained psychiatrist with access to medications and a psychologist would be available to provide medical and psychotherapeutic support if needed. Furthermore, nursing support would be available at the clinical research facility in case of need. Participants who are unable to tolerate any aspects of the protocol will be withdrawn from the study. Data protection: The study will be conducted in compliance with the relevant UK directive (Data Protection Act, 1998) and information relating to participants collected for the study will be kept confidential and secure, with the participants identified by a code. An appropriate case report form (CRF) that will comprise spreadsheets to store data electronically will be used for this study, with access restricted to study personnel and level of access set to maintain privacy and confidentiality of participant information. All hardcopy data and source files will be stored in limited access facilities (locked cupboards) accessible only to study staff inside locked premises at the Department of Psychosis Studies, Institute of Psychiatry, London, UK. An appropriate case report form (CRF) will be used for this study. The proposed CRF for each study participant would be an anonymised electronic document comprising spreadsheets to store data captured on the various study rating instruments. These CRFs would be maintained in an electronic database stored in a computer located within secure access facilities within the Department of Psychosis Studies, Institute of Psychiatry. Access to the CRFs and electronic database would be password protected and would be monitored and available to only study personnel and anybody that may require access for regulatory reasons. The level of access would be set to maintain the privacy and confidentiality of participant information. Source documentation (a ÔSource FileÕ including information that may be documented in the patientÕs medical record) that substantiates the information collected in the CRF would be maintained for at least 20 years and longer if required by local regulations (other study-related documentation as outlined in the Good Clinical Practice guideline would also need to be retained for the same period of time). The CRF will be managed by staff involved in the study. Study participants would not be identified by name in the CRF where anonymised information will be recorded.
Withdrawal criteria:
In accordance with the Helsinki declaration and other applicable regulations, study participants will have the right to withdraw from the study at any time and for any reason without prejudice to his or her future medical care. Additionally, participants who experience adverse events (AE; including clinically significant laboratory result), which in the opinion of the investigator would compromise the continued safe participation of the subject in the study or who experience serious adverse events will be withdrawn from the study. Exit criteria: UHR subjects who experience progression to a first episode of psychosis (operationalized using severity thresholds proposed by Morrison and colleagues(48): score of ≥ 4 on hallucinations or delusions or ≥ 5 on conceptual disorganization) will exit from the study. Clinical team involved in the care of the participant will be informed and a referral will also be made to the locality first-episode psychosis team. Medication Supply, Storage and Randomisation: Study medications would be obtained from THC-Pharm (Frankfurt, Germany). All Study medications (both active drug and placebo) would be manufactured, packaged, labelled and supplied by STI pharmaceuticals according to GMP guidelines. Study medications would be stored at the Maudsley hospital pharmacy. Randomization of participants into the two treatment groups and blinding would be carried out by an experienced pharmacist at the Maudsley hospital pharmacy.
VI. DATA PRESERVATION FOR SHARING:
The study data will be collected in an appropriate eCRF in an anonymised format, which along with source data will be stored for 20 years or longer.
VII. POTENTIAL BENEFITS/ IMPLICATIONS:
This study will help clarify the role of the endocannabinoid system in psychotic disorders and may help identify novel candidate pathways/ molecules as targets for drug discovery. , which was administered at baseline before drug administration. Finally, 2 CHR subjects were excluded, one from each of the CBD-treatment and placebo-treatment arms, after failing to correctly perform the imaging task, resulting in n=15 participants in the CHR-CBD group and n=16 in the CHR-PLB group.
Experimental procedure
Using a parallel-group, double-blind, randomized and placebo-controlled design, CHR participants were randomized to either placebo (CHR-PLB) or CBD (CHR-CBD) treatment arms. Both CHR participants and researchers involved in data collection of CHR participants were blind to treatment allocation. A randomisation sequence was generated by STI pharmaceuticals across the two arms of the study using a blocking factor to ensure even distribution across the two arms. On recruitment of a study participant, an un-blinded clinical trial pharmacist, who was not involved with the rest of the study, allocated the participant to ). Therefore, we opted for the 600 mg/day dose of CBD for the present study based on previous evidence that CBD doses of 600-800 mg/day were as effective at reducing symptoms as antipsychotic medication (amisulpiride) 5 in patients with first-episode psychosis. Subjects then underwent functional magnetic resonance imaging (fMRI) whilst performing a verbal paired associate learning task lasting approximately 12 minutes. MRI scanning started 3 hours after the taking the study drug (CBD or placebo), as previous research has shown that CBD levels reached its peak around 3 hours following oral administration 6 . HC participants were investigated under identical conditions, except that they did not receive any study drug.
On the study day, all participants consumed a light standardised breakfast in front of the researchers, and were asked to have refrained from cannabis for 96 hours, alcohol for a minimum of 24 and nicotine for 6 hours before scanning. Furthermore, they are asked not to have used any other recreational drugs for two weeks before the study day. A urine sample prior to scanning was used to screen for use of illicit drugs. Three hours prior to scanning, subjects in the CBD-CBD group received one cannabidiol capsule (600mg, approx. 99.9%
pure, THC-Pharm, Frankfurt, Germany), whilst those in the CHR-PLB group received a visually identical flour (placebo) capsule.
Verbal paired associate learning task
Inside the MRI scanner, subjects performed a verbal paired associate (VPA) learning task that we have previously used in conjunction with fMRI and pharmacological challenge 7, 8 , including CBD administration . Participants were familiarized with the task during a training session with a set number of trials outside of the scanner using different words from those presented during imaging.
For each participant, the blood oxygen level-dependent haemodynamic (BOLD) response of the brain during each encoding and recall block, measured using a 3T MRI scanner, was contrasted with that during the baseline condition.
Image Acquisition
Images were acquired using a 3T MRI scanner (GE Medical Systems, Milwaukee, Wisconsin). One hundred and forty seven T2*-weighted volumes were acquired using a gradient echo sequence axially in 39 x 3mm slices with a 3.3mm slice gap running parallel to the intercommissural (AC-PC) plane (FOV 24×24 cm and matrix 64×64). A 30ms echo time, 90° flip angle, and compressed acquisition with a 2s repetition time and 3s silence was also used. A high-resolution inversion recovery image data set was acquired to facilitate anatomic localization of activation.
Data Analysis
Image analysis: The fMRI data were analyzed with software developed at the Institute of Psychiatry, Psychology and Neuroscience (XBAM, version 4.1), using a nonparametric approach to minimize assumptions (https://www.kcl.ac.uk/ioppn/depts/neuroimaging/research/imaginganalysis/Software/XBAM. aspx) 12, 13 about the distribution of the data. In contrast to other commonly employed image analysis approaches, XBAM, in particular, does not assume a Gaussian population distribution of fMRI signals in the brain. This is an assumption that is very difficult to test in small groups with neuroimaging data and when tested, is found to be violated 12, 13 . Instead, XBAM employs median statistics and permutation-based rather than normal theory-based approaches for statistical inference. Therefore it is less sensitive to the effects of outlier values that may bias the distribution of the data 14 . In this method, the test statistic is computed by standardizing for individual differences in residual noise before embarking on a secondlevel, multi-subject testing, using robust permutation-based methods, employing a mixedeffects approach.
Images were corrected for subject motion 15 and spatially smoothed using a 7.2 mm fullwidth-at-half-maximum Gaussian filter to average the relative intensities of neighbouring voxels. Responses to the experimental paradigm were detected by convolving each component of the design with two gamma-variate functions (peaks at 4 and 8s) to model the blood oxygen level-dependent (BOLD) response. Then, using the constrained BOLD effects model, a best fit between the weighted sum of these convolutions and the change over time at each voxel was computed 16 . Following least-squares fitting of this model, a sum of squares (SSQ) ratio statistic was estimated at each voxel. This consisted of the ratio of the SSQ of deviations from the mean image intensity due to the model (over the whole time series), to the SSQ of deviations due to the residuals. These data were then permuted using a wavelet-based method described and characterized previously 17 , to determine significantly activated voxels specific to each condition. Activated voxels were then grouped into clusters using a method described before 18 , which has been shown to give excellent cluster-wise type 1 error control.
SSQ ratio maps for each individual were transformed into standard stereotactic space 19 using a two-stage warping procedure 12 for the purpose of localization of activations. As a first step, an average image intensity map for each individual over the course of the experiment was computed. We then computed the transformations required to map this image to the structural scan for each individual and then from 'structural space' to the Talairach template by maximizing the correlation between the images at each stage. The SSQ ratio and BOLD effect size maps were then transformed into Talairach space using these transformations.
Group activation maps were computed for each group in each drug condition by determining the median SSQ ratio at each voxel (over all individuals) in the observed and permuted data maps. Medians were used to minimize outlier effects. The distribution of median SSQ ratios over all intracerebral voxels from the permuted data was then used to derive the null distribution of SSQ ratios, which allows group activation maps to be thresholded at the desired voxel or cluster-level type 1 error rate. This gave group activation maps for each condition that could be compared against each other using non-parametric repeated-measure analysis of variance (ANOVA) 12 . The voxel-wise statistical threshold was set at p=0.05 and the cluster-wise thresholds were adjusted to ensure that the number of false positive clusters per brain would be <1 (regions that survive this critical statistical threshold and the corresponding p values are reported). This excluded any areas of activation, which did not meet this threshold of significance. By conducting analyses at a cluster-level, data from more than one voxel is integrated into the test statistic giving greater sensitivity and it also allows for a reduction in the search volume or overall number of required tests for whole brain analysis. In comparison to analysis at the voxel level, cluster level analyses with a nonparametric approach thereby helps mitigate the multiple comparisons problem 20 .
The BOLD response in each subject was modelled using only trials associated with correct responses in the recall condition, and responses confirming attention to the task during encoding. To investigate the differences in brain activation between the CHR-PLB and HC subjects the respective group activation maps were contrasted using a between-group, nonparametric analysis of variance. Group activation maps for the CHR-CBD and CHR-PLB subjects were similarly contrasted using a between-group, non-parametric analysis of variance to investigate the effect of single dose of CBD on brain activation in CHR patients relative to placebo treatment. To test the hypothesis that activation in the CHR-CBD group would be intermediate between that of HC and CHR-PLB subjects, a non-parametric analysis of variance was performed to examine whether a linear relationship in brain activation (CHR-PLB > CHR-CBD > HC or CHR-PLB < CHR-CBD < HC) existed within the whole brain. 
